Repligen (NASDAQ:RGEN) Now Covered by Canaccord Genuity Group

Canaccord Genuity Group began coverage on shares of Repligen (NASDAQ:RGEN) in a research note issued to investors on Tuesday morning,Briefing.com Automated Import reports. The firm issued a hold rating and a $165.00 price objective on the biotechnology company’s stock.

Several other analysts also recently weighed in on RGEN. Wolfe Research began coverage on shares of Repligen in a research note on Thursday, November 14th. They set a “peer perform” rating for the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $205.00 target price on shares of Repligen in a research report on Thursday, September 26th. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a research report on Friday, November 22nd. Canaccord Genuity Group assumed coverage on Repligen in a report on Tuesday. They issued a “hold” rating and a $165.00 price objective for the company. Finally, Wells Fargo & Company started coverage on shares of Repligen in a report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 target price on the stock. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $185.20.

Repligen Price Performance

Shares of RGEN stock opened at $158.14 on Tuesday. The stock has a 50 day moving average price of $143.15 and a 200 day moving average price of $141.68. The firm has a market capitalization of $8.86 billion, a P/E ratio of -427.41, a P/E/G ratio of 4.64 and a beta of 0.96. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen has a 52-week low of $113.50 and a 52-week high of $211.13.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. The firm had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The business’s revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.23 earnings per share. As a group, sell-side analysts predict that Repligen will post 1.54 earnings per share for the current year.

Institutional Trading of Repligen

Several hedge funds and other institutional investors have recently made changes to their positions in RGEN. Champlain Investment Partners LLC increased its position in Repligen by 149.0% during the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock valued at $211,464,000 after buying an additional 850,345 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Repligen by 21.0% during the second quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock valued at $172,749,000 after acquiring an additional 237,884 shares in the last quarter. Conestoga Capital Advisors LLC raised its position in shares of Repligen by 26.7% in the 2nd quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock valued at $119,363,000 after purchasing an additional 199,322 shares during the last quarter. Thrivent Financial for Lutherans boosted its stake in Repligen by 6.1% in the 3rd quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock worth $95,037,000 after purchasing an additional 36,773 shares in the last quarter. Finally, DF Dent & Co. Inc. grew its position in Repligen by 31.0% during the 3rd quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock worth $87,852,000 after purchasing an additional 139,615 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.